###### Strengths and limitations of this study

-   This is the randomised controlled trial to observe the efficacy and safety of preoperative ultrasound-guided superficial cervical plexus block on postoperative analgesia in patients undergoing craniotomy via suboccipital retrosigmoid approach.

-   The results will optimise postoperative analgesia in patients undergoing infratentorial craniotomy, thereby improving prognosis of the patients.

-   This is a single-centre clinical trial design which might limit the generalisation of the conclusion.

Background {#s1}
==========

The procedure of craniotomy was previously assumed to be less painful than other sites of surgeries.[@R1] However, in the prospective study of patients undergoing craniotomy, Gottschalk *et al* found that the incidence of postoperative pain was as high as 87%, among of 55% patients experienced moderate-to-severe pain.[@R4]

Post-craniotomy pain is mainly caused by scalp incision, with abundant free nerve endings. After incision, noxious stimulus signals from the scalp is received by the trigeminal branches or cervical plexus branches, and then transmitted through the trigeminal nucleus and the dorsal horn of the spinal cord to the hypothalamus and cerebral cortex. The whole process is regulated by a variety of inflammatory mediators, peripheral nerve pathways and central nervous system.[@R5]

The pain severity after craniotomy is closely associated with surgical approach. Gottschalk *et al* evaluated pain after craniotomy and found that the infratentorial approach was associated with severe postoperative pain and more perioperative analgesic requirements.[@R4] Rimaaja *et al* reported that 32% of patients had no or only mild headache prior to removal of the cerebellopontine angle area mass, while 64% of patients developed severe headache after craniotomy.[@R6] The high incidence of postoperative pain after craniotomy through infratentorial approach, especially suboccipital retrosigmoid approach may be related to the injury of neck muscles and posterior occipital muscles by the surgical approach, as well as the special position of the head and neck during craniotomy, leading to postoperative muscle spasm.[@R7] Therefore, it is necessary to explore an ideal analgesic modality that can effectively provide surgical analgesia with minimal or no systemic changes for this population.

The skin incision is the main source of pain during craniotomy. Scalp nerve block has been proven to be an excellent alternative analgesic choice in supratentorial surgeries.[@R9] However, for the suboccipital retrosigmoid craniotomy, the scalp innervation area is insufficient to cover the incision, resulting defective nerve blockage. Therefore, it is necessary to explore an analgesic modality to provide a more ideal analgesic regimen for patients undergoing suboccipital retrosigmoid craniotomy.

The cervical plexus is from the anterior branch of C1 to C4 cervical nerve, divided into superficial plexus and deep plexus. The cutaneous branches of the superficial cervical plexus include the lesser occipital nerve, the greater auricular nerve, transverse cervical nerve and supraclavicular nerve, innervating the incision area of the suboccipital sigmoid sinus approach craniotomy.[@R12] Therefore, the superficial cervical plexus block (SCPB) is a potential candidate to satisfy the analgesic requirement of retrosigmoid craniotomy. Girard *et al* observed the effect of transitional analgesia from SCPB after elective infratentorial or occipital craniotomy in 30 patients.[@R13] In the control group, 0.1 mg/kg morphine was administrated after close of the dura. It was found that the effect of SCPB on postoperative analgesia was not inferior to administration of morphine after dura closure. However, the sample size estimation they made is too small. Second, SCPB wasn't guided by ultrasound. The analgesic effect of SCPB may not be fully guaranteed. In addition, no related adverse effects were reported in that study. However, the study provided us a feasible method of SCPB analgesia for suboccipital retrosigmoid craniotomy.

With the continual development of visualisation techniques, ultrasound-guided nerve blocks have become increasingly popular.[@R14] Ultrasound-guided SCPB, the operator can directly see adjacent anatomical structure, inject the local anaesthetic into the correct anatomical level, avoid accidental injury during the puncture and avoid the unexpected deep cervical plexus block. Ultrasound-guided SCPB has the advantages of faster onset of action, less dosage, high success rate and fewer complications.[@R17]

Therefore, we propose the hypothesis that preoperative ultrasound-guided SCPB could safely and effectively provide analgesia for patients undergoing craniotomy via suboccipital retrosigmoid approach. The objective is to compare the cumulative consumption of postoperative opioids between groups.

Methods {#s2}
=======

Study design {#s2-1}
------------

This is a prospective, single-centre, randomised, paralleled-group controlled trial ([figure 1](#F1){ref-type="fig"}.) being conducted at Beijing Tiantan Hospital, Capital Medical University, China. The study was registered within ClinicalTrials.gov on 29 June 2019. Preoperative interviews will be conducted by specially trained research assistants to inform patients of the study objectives, risks and benefits and to obtain written informed consent from patients or legal representatives. The schedule of enrolment and assessments is shown in the Standard Protocol Items: Recommendations for Interventional Trials ([figure 2](#F2){ref-type="fig"}).

![Consolidated Standards of Reporting Trials flow diagram. NRS, Numerical Rating Scale; PCIA, patient-controlledintravenous analgesia; SCPB, superficial cervical plexus block.](bmjopen-2019-034003f01){#F1}

![Standard Protocol Items: Recommendations for Interventional Trials. NRS, Numerical Rating Scale; PCA, patient-controlledanalgesia; SCPB, superficial cervical plexus block.](bmjopen-2019-034003f02){#F2}

Study population {#s2-2}
----------------

### Inclusion criteria {#s2-2-1}

Patients scheduled to undergo elective suboccipital retrosigmoid craniotomy will be recruited for screening eligibility 1 day before surgery. Inclusion criteria include age between 18 and 65 years, and American Society of Anesthesiologists (ASA) physical status I to III.

### Exclusion criteria {#s2-2-2}

Exclusion criteria include refuse to provide written informed consent, local infection, preoperative impairment of consciousness and cognitive function, uncontrolled hypertension, inability to communicate; allergic to experimental drugs; history of drug abuse; history of chronic headache; aphasia and hearing impairment; second craniotomy; body mass index \<18.5 kg/m^2^ or \>35.0 kg/m^2^.

Randomisation and blinding {#s2-3}
--------------------------

Randomisation will be conducted via a computer-generated table by an independent research assistant who will pack the allocation sequence with identical shape and size opaque envelopes and distribute to the researcher. The researcher will open the envelopes and perform a SCPB or only puncture based on the grouping. Patients will be randomly assigned to two groups with a 1: 1 ratio. The researcher assistant, patients, the anaesthesiologist responsible for intraoperative management and outcome assessors will all be blinded to the allocation until the completion of the study analysis unless specific circumstances, such as the occurrence of a serious adverse event.

Data collection {#s2-4}
---------------

After obtaining informed consent, an independent research assistant will initiate baseline information collection 1 day before surgery. Basic demographic information, including gender, age, vital signs, height, weight, past medical history/family history, medication history, supplementary examination, assessment (ASA classification, headache and severity, treatment, dizziness, tinnitus, facial paralysis, nausea, vomiting and other symptoms) will be collected. All personal information will be kept strictly confidential for research purposes only. The assessment of primary and other secondary outcomes will be performed by trained research assessors who are blinded to the group allocation.

Intervention {#s2-5}
------------

Patients will be randomly assigned to the SCPB group or the control group. Peripheral venous access will be established on arrival in operating room. After anaesthesia induction, SCPB will be performed under the guidance of ultrasound (Hitachi Company, Noblus) by the independent researcher who will not involve in intraoperative management or postoperative follow-up. Patients will be at supine position with ipsilateral shoulder relaxed and slightly elevated while head tilting to the opposite side. After marking the midpoint of the posterior border of clavicular head of the sternocleidomastoid muscle (about cricoid cartilage level, about 3 to 4 cm above the clavicle), an ultrasound probe (50 mm high frequency linear array) warped with sterilise plastic dress will be placed in the transverse position at the previous measuring mark. The scanning depth will be 3 to 4 cm and the focussing position will be 2 to 3 cm. After confirming the sternocleidomastoid muscle, we move the probe backwards until the posterior border of the sternocleidomastoid muscle in the centre of the screen, and identify the investing fascia and prevertebral fascia from the shallow to the deep layer. Using long-axis in-plane technique, a 50 mm long, 20 G short bevel needle will be inserted from the lateral border of sternocleidomastoid muscle. Under guidance of ultrasound, we will confirm the needle tip locating between the deep layer of investing fascia and the superficial layer of prevertebral fascia, close to the border of sternocleidomastoid muscle. After negative aspiration of blood and cerebrospinal fluid, 1 mL of 0.5% ropivacaine will be administered to confirm the location of the needle tip. Then, 10 mL of 0.5% ropivacaine will be infused on the superficial layer of prevertebral fascia. The puncture site will be covered with opaque infusion dressing after completing of SCPB.

In the control group, the puncture will also be performed by ultrasound guidance, covered with opaque infusion dressing but performed without infusion.

Concomitant treatment {#s2-6}
---------------------

Routine monitoring will include ECG, pulse oxygen saturation, non-invasive blood pressure (NIBP), body temperature, minimal alveolar concentration (MAC) of inhalation agent and bispectral index (BIS). Continuous arterial pressure, urine output and end-tidal carbon dioxide PaO2 (ETCO~2~) will be monitored after anaesthesia induction. All patients will be premedicated with midazolam (0.05 mg/kg) intravenously 5 min before anaesthesia induction. Anaesthesia will be induced with propofol (1.5 to 2.5 mg/kg), sufentanil (0.3 to 0.4 µg/ kg), and rocuronium (0.9 mg/kg) or cisatracurium (0.2 mg/kg). After tracheal intubation, mechanical ventilation will be performed, at a tidal volume of 6 to 8 mL/kg, a respiratory rate of 12 to 15/min, an inspiratory/expiratory ratio of 1:2, a 50% fraction of inspired oxygen in the air and fresh gas at a flow rate of 2 L/min to maintain the ETCO~2~ between 35 and 40 mm Hg.

Anaesthesia will be maintained with combined intravenous anaesthesia and inhalational anaesthesia. Along with the inhalational anaesthesia maintained with 0.5 MAC, infusion of remifentanil (0.1 to 0.4 µg/kg/min) and propofol (3 to 8 mg/kg/h) will be maintained to keep BIS values between 40 and 50. No muscle relaxant will be used during the procedure to meet intraoperative electronical physiological neuromonitoring requirements. No additional local anaesthetics or analgesics will be administered intraoperatively. Propofol and remifentanil infusion will be discontinued at the end of surgery.

The patients will be extubated after full recovery from anaesthesia and transferred to the post-anaesthesia care unit (PACU). The patients will remain in the PACU for 120 min and receive nasal oxygen inhalation with ECG, NIBP, pulse oximetry monitoring. Sufentanil-loaded electric analgesia pumps which pre­programmed by the research assistant will be connected to the patients for routine postoperative analgesia. The patient-controlled intravenous analgesia (PCIA) pumps will be filled with sufentanil (100 µg) and ondansetron (16 mg) diluted in 100 mL of 0.9% saline. This regimen will provide a bolus of 1 µg sufentanil on demand with a 10 min lockout time, without continuous background infusion dose or loading dose. Insufficient postoperative analgesia will be defined as an Numerical Rating Scale (NRS) score \>4 lasting over 15 min or \>6. Once inadequate postoperative analgesia was confirmed, patients will receive rescue analgesic. If the patient vomit or report nausea for more than 15 min, rescue antiemetic will be administered. The type, the frequency and the dose of rescue analgesic and antiemetic will be recorded. The reason for administration will also be recorded giving drugs with analgesic or/and antiemetic.

Physiological parameters, the total doses of anaesthetic drugs and vasoactive drugs will be recorded. Fluid input and output will also be closely monitored and recorded. Anaesthesia and surgery duration will be summarised.

Outcomes and safety measures {#s2-7}
----------------------------

The aim of this study is to observe the effect of SCPB on postoperative analgesia in patients with suboccipital retrosigmoid craniotomy. During preoperative visits, patients will be informed of the score how to assess the pain, analgesic satisfaction, sleep quality and anaesthesia recovery quality.

Primary outcome {#s2-8}
---------------

The primary outcome is the cumulative consumption of sufentanil by the PCIA within 24 hours after surgery. The primary outcomes will be assessed by trained research assistants at 24 hours after surgery through reading the PCIA data.

Secondary outcomes {#s2-9}
------------------

The secondary outcomes include the other efficacy parameters and safety outcomes.

1.  The first time point that the patients use PCIA, the total and effective requests of PCIA at five different time points after surgery (1, 2, 4, 24, 48 hours) and the cumulative consumption of sufentanil at four different time points (1, 2, 4, 48 hours) after surgery.

2.  Pain Severity Score: Pain will be assessed at five time points after surgery. The degree of surgical incision pain will be assessed at rest and on movement NRS pain score. Insufficient postoperative analgesia is defined as an NRS score that exceeds 4 lasted for 15 min or exceeds 6. Information of analgesic drugs administrated in case of insufficient postoperative analgesia was also recorded. Pain severity score in NRS is 0 to 10, 0 representing no pain and 10 representing worst pain imaginable.

3.  Anaesthesia Recovery Quality Score: Anaesthesia Steward Emergence Scale[@R19] will be used at 1 and 2 hours after surgery to evaluate the recovery quality of anaesthesia. Anaesthesia recovery quality score will be assessed by the Anaesthesia Steward Emergence Scale which is divided into three parts: the degree of wakefulness (2 points for complete recovery, 1 point for response to stimulation, 0 point for no response to stimulation), the degree of airway patency (2 points for cough according to the doctor\'s order, 1 point for maintenance of airway patency without support, 0 point for support required for respiratory tract) and the degree of limb mobility (2 points for conscious activities of limbs, 1 point for unconscious activities of limbs, 0 point for no activities of limbs).

4.  Analgesic satisfaction and sleep quality: Patient satisfaction with overall pain management and sleep quality will be evaluated separately at 24 and 48 hours after surgery using NRS. Analgesic satisfaction score in NRS is 0 to 10, 0 representing extremely dissatisfied and 10 representing extremely satisfied. Sleep quality score in NRS is scored as 0 to 10, 0 representing unable to sleep and 10 representing deep sleep.

5.  Adverse events: Ramsay score[@R20] and nausea and vomiting scores as well other adverse events (dizziness, fatigue, haematoma, local anaesthetic poisoning and hoarseness) will be evaluated at the five time points after surgery.

Sample size calculation {#s2-10}
-----------------------

We estimate the sample size according to the primary outcome of postoperative-24-hour PCIA sufentanil consumption by using PASS 2011 software (NCSS LLC). Based on the previous literature,[@R21] Akcil *et al* demonstrated the mean (95% CI) postoperative cumulative morphine consumption was 30 mg (25 to 35) in the scalp block group and 50 mg (40 to 60) in the control group. Considering that 1 mg morphine is equivalent to 1 µg sufentanil, we estimated the scalp block in their study reduced PCIA sufentanil consumption by 20 µg within postoperative 24 hours. In the routine practice without SCPB, we also apply PCIA for the patients undergoing craniotomy via suboccipital retrosigmoid approach with the dosage of sufentanil as 50 µg during the first 24 hours after surgery. So, we estimated the effect size of mean as 20 µg with the SD of 30 µg for the SCPB group comparing with the control group. The sample size of 106 patients will be sufficient to detect the difference at a two-tailed significant level of 0.05 and a power of 90% using Student's t-test, with a drop-out rate of 10%.

Statistical analysis {#s2-11}
--------------------

Analysis will be done using SPSS software (V.23.0). We will apply the intention-to-treat and per-protocol analysis on the primary outcome. If necessary, consider the number of missing outcomes as poor prognosis and conduct sensitivity analysis. The continuous variables will be summarised with mean (SD) or median (IQR), depending on normality determined with Shapiro-Wilk test. Normally distributed and continuous variables will be compared with Student\'s t-test, while skewed variables will be compared using the Mann-Whitney U test. The categorical variables will be described as counts (percentages) and compared with X^2^ analysis or Fisher's exact test. The repeated measurement data will be analysed by repeated measurements of variance analysis. Bonferroni correction will be used for multiple comparisons. A significance level of p\<0.05 was used to indicate statistical significance.

Reporting of adverse events {#s2-12}
---------------------------

All adverse events will be closely monitored until a stable situation has been reached. The chief investigator will be informed of any serious adverse events and determine the severity and causality of these events. All adverse events associated with this study will be recorded and reported to the ethics committee as part of the annual report. The chief investigator will be responsible for getting the details about causes of adverse events, treatment measures, prognosis and reporting serious adverse events to the Ethics Committee immediately.

Protocol amendment {#s2-13}
------------------

The chief investigator will be responsible for any decision to amend the protocol. If there is any modification (eg, changes to eligibility criteria, outcomes, analyses) the principle investigator will communicate and gain approval from the China Ethics Committee of Registering Clinical Trials prior to implementation, and communicate with relevant other parties (eg, investigators, trial participants, trial registries, journals, regulators)

Discussion {#s3}
==========

An ideal analgesic should be able to provide analgesia for entire surgical period and with minimal or no systemic changes. Meanwhile, the interference on consciousness and postoperative neurological function should be minimised during the recovery and evaluation period. At present, PCIA with opioid is the most common analgesia modality for patients received craniotomy.[@R21] However, undesirable effects of opioids, including respiratory depression, nausea, vomiting, urinary retention, etc, not only bring discomfort to patients, but also affect neurological function evaluation by neurosurgeons.[@R23] Besides opioids, non-steroidal anti-inflammatory drugs, another common analgesia agent is not suitable for postoperative analgesia after neurosurgery due to its effect on coagulation.[@R24] Gabapentin is an adjuvant antiepileptic agent with some analgesic effects. Our previous research demonstrated that oral gabapentin relieved early postoperative pain, with increased depth of sedation in post-craniotomy, which indicated gabapentin was not the appropriate candidate for postoperative neurosurgical analgesia.[@R25] Therefore, it is necessary to explore an ideal analgesic modality that can effectively provide surgical analgesia with minimal or no systemic changes for this population.

This is a prospective, single-centre, randomised, parallel-group controlled trial to assess the efficacy and safety of preoperative ultrasound-guided SCPB for analgesia in patients undergoing suboccipital retrosigmoid craniotomy. With the continuous development of ultrasound guidance technology, utilisation of visualised nerve block became more popular in clinical practice.[@R15] We design the current study to use ultrasound-guided SCPB to explore the efficacy and safety of postoperative analgesia in patients undergoing suboccipital sigmoid approach for craniotomy. Although ultrasound guidance greatly improves the efficacy and safety of the block, we still can't ignore the risk associated with the cervical plexus block. Therefore, in this study we will observe these complications such as haematoma, dizziness, fatigue, local anaesthetic poisoning and hoarseness. At the same time, in order to ensure the accuracy and consistency of ultrasound-guided puncture, the anaesthesiologists will receive specific training before the first patients are enrolled, the corresponding ultrasound image data of puncture will be preserved, so as to ensure the uniformity of block effect in each patient.

Although SCPB may reduce post-craniotomy pain, it is not routinely used in our current clinical practice. To maintain the analgesic effect on the patients in the control group, the patients will be given the same analgesic dosage regimen following the clinical routine of our medical centre, which fully ensure that the patients are safe and painless during surgery. Postoperative PCIA analgesia will be routinely given to all patients, and rescue analgesics will be promptly administered when analgesia is insufficient.

Our study will improve the ideal analgesic regimen for patients undergoing suboccipital retrosigmoid craniotomy, so as to reduce perioperative stress response and complications, improve patient satisfaction and early recovery.

Patient and public involvement {#s3-1}
------------------------------

Patients and the public were not directly consulted in the development of the research question or outcome measures. Patients were not involved in the design, the recruitment and conduct of the study. At the completion of this trial, a manuscript will be prepared to present the trial results. Results of the final study will be disseminated to all study participants through their preferred method of communication indicated at the time of enrolment. The burden of intervention will not be taken by participants themselves.
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